Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Aimmune Therapeutics, Inc. (AIMT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/19/2020 8-K Quarterly results
08/31/2020 8-K Quarterly results
07/30/2020 8-K Quarterly results
05/28/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2020 8-K Quarterly results
02/27/2020 8-K Quarterly results
02/05/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock",
"Amended and Restated Registration Rights Agreement, by and between the Company and Nestle Health Science US Holdings, Inc",
"Amended and Restated Standstill Agreement, by and between the Company and Nestle Health Science US Holdings, Inc",
"Development Programs",
"Securities Purchase Agreement, by and between the Company and Nestle Health Science US Holdings, Inc",
"Aimmune Licenses Exclusive Worldwide Rights to Xencor's XmAb ® 7195 for the Development of Next-Generation Food Allergy Treatments"
01/31/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"FDA Approves Aimmune's PALFORZIA ™ as First Treatment for Peanut Allergy"
12/20/2019 8-K Quarterly results
11/15/2019 8-K Quarterly results
11/06/2019 8-K Quarterly results
Docs: "Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights --Webcast and conference call today at 4:30 p.m. ET --"
08/08/2019 8-K Quarterly results
Docs: "Aimmune Therapeutics Announces Second Quarter 2019 Financial Results and Provides Operational Highlights --Webcast and conference call today at 4:30 p.m. ET --"
06/18/2019 8-K Quarterly results
05/30/2019 8-K Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Submission of Matters to a Vot...
Docs: "AIMT_Code of Business Conduct and Ethics revised"
05/14/2019 8-K Entry into a Material Definitive Agreement
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 10, 2019 AIMMUNE THERAPEUTICS, INC. Delaware 001-37519 45-2748244 8000 Marina Blvd, Suite 300 Brisbane, CA 94005 Registrant's telephone number, including area code: 614-5220 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement co..."
05/08/2019 8-K Quarterly results
Docs: "Aimmune Therapeutics Announces First Quarter 2019 Financial Results and Provides Operational Highlights"
03/25/2019 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 25, 2019 AIMMUNE THERAPEUTICS, INC. Delaware 001-37519 45-2748244 8000 Marina Blvd, Suite 300 Brisbane, CA 94005 Registrant's telephone number, including area code: 614-5220 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement ...",
"European Phase 3 Trial of Aimmune Therapeutics' AR101 Meets Primary Endpoint"
03/18/2019 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 18, 2019 AIMMUNE THERAPEUTICS, INC. Delaware 001-37519 45-2748244 8000 Marina Blvd, Suite 300 Brisbane, CA 94005 Registrant's telephone number, including area code: 614-5220 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement ..."
02/28/2019 8-K Quarterly results
Docs: "Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights"
01/14/2019 8-K Other Events
01/04/2019 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 3, 2019 AIMMUNE THERAPEUTICS, INC. Delaware 001-37519 45-2748244 8000 Marina Blvd, Suite 300 Brisbane, CA 94005 Registrant's telephone number, including area code: 614-5220 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement...",
"Aimmune Therapeutics and KKR Enter into $170M Loan Agreement to Fund AR101 Commercialization and Pipeline Advancement"
01/02/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SIGNATURES"
11/28/2018 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 28, 2018 AIMMUNE THERAPEUTICS, INC. Delaware 001-37519 45-2748244 8000 Marina Blvd, Suite 300 Brisbane, CA 94005 Registrant's telephone number, including area code: 614-5220 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commenceme..."
11/19/2018 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 18, 2018 AIMMUNE THERAPEUTICS, INC. Delaware 001-37519 45-2748244 8000 Marina Blvd, Suite 300 Brisbane, CA 94005 Registrant's telephone number, including area code: 614-5220 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commenceme...",
"Landmark PALISADE Trial of AR101 Published in",
"Company slide presentation"
11/13/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 11, 2018 AIMMUNE THERAPEUTICS, INC. Delaware 001-37519 45-2748244 8000 Marina Blvd, Suite 300 Brisbane, CA 94005 Registrant's telephone number, including area code: 614-5220 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commenceme...",
"Aimmune Therapeutics Announces Additional Equity Investment by Nestlé Health Science"
11/08/2018 8-K Quarterly results
Docs: "Aimmune Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Highlights"
11/06/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/08/2018 8-K Quarterly results
Docs: "Aimmune Therapeutics Announces Second Quarter 2018 Financial Results"
06/11/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SIGNATURES",
"Aimmune Therapeutics Appoints Dr. Jayson Dallas as CEO"
05/25/2018 8-K Submission of Matters to a Vote of Security Holders
05/08/2018 8-K Quarterly results
Docs: "Aimmune Therapeutics Announces First Quarter 2018 Financial Results"
03/12/2018 8-K Quarterly results
Docs: "Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results"
02/26/2018 8-K Asset disposition
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : February 21, 2018 AIMMUNE THERAPEUTICS, INC. Delaware 001-37519 45-2748244 8000 Marina Blvd, Suite 300 Brisbane, CA 94005 Registrant's telephone number, including area code: 614-5220 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commenceme...",
"Underwriting Agreement, among Aimmune Therapeutics, Inc. and Merrill, Lynch, Pierce, Fenner & Smith Incorporated, as representative of the underwriters named therein",
"Opinion of Latham & Watkins LLP"
02/20/2018 8-K Investor presentation
Docs: "FORM 8-K",
"Aimmune Therapeutics' Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients with Peanut Allergy",
"Company Presentation"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy